CClinicalTrials.gg
Not yet recruitingNCT06190080Obs-OEUpdated Jan 16, 2024

Outcome of Children With Eosinophilic Esophagitis

An interventional study of Digestive endoscopy in Esophagitis, Eosinophilic, sponsored by Fondation Lenval. Not yet recruiting at 1 site in France. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-01-16.

Sponsored by Fondation Lenval · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Study summary

The investigator would like to create a prospective cohort of patients in order to describe eosinophilic esophagitis with the specificities corresponding to our geographical territory, and to study their evolution at 3 months, 6 months, 12 months, 18 months and 24 months.

This study would also enable us to investigate the quality of life of these chronically ill patients

Read the detailed description

The investigator would like to create a prospective cohort of 16 patients included over 2 years in order to determine the rate of complete remission (clinical, endoscopic and histological) at 3 months, 6 months, 12 months, 18 months and 24 months of treatment initiation. It is also planned to describe this cohort of pediatric EO patients at inclusion and throughout follow-up, and to study their quality of life.

Follow-up visits is organized every 3 months with a gastropediatrician, who assesses the patient's symptoms (PEESS score) and quality of life (PedsQL eosinophilic esophagitis module and PedsQL 4.0 Generic Core Scales).

If treatment needs to be introduced or changed, a digestive endoscopy with biopsies will be carried out at 3 months to determine whether the patient is in remission or not.

02

Conditions studied

  • Esophagitis, Eosinophilic

Keywords

  • children
  • eosinophilic esophagitis
  • life quality
03

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of OE according to the diagnostic criteria of the PNDS published in July 2022
  • Due to start treatment.
  • informed consent from one of the 2 parents or the representative of parental authority.
  • Membership of a social security scheme.

Exclusion criteria

Exclusion Criteria:

-

04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Other
    Management of eosinophilic esophagitis

    Follow-up visits are always organized in the same way. A consultation with a gastropediatrician will take place, with assessment of symptoms (PEESS score) and quality of life (PedsQL module for eosinophilic esophagitis and PedsQL 4.0 Generic Core Scales). Then, if treatment needs to be introduced or changed, a digestive endoscopy with biopsies will be carried out at 3 months to determine whether the patient is in remission or not. Depending on the results, the patient may be advised to adapt or maintain the current treatment.

    Other: Digestive endoscopy

Interventions

  • OtherDigestive endoscopy

    Digestive endoscopies are performed in the operative room under general anaesthetic 3 months after the introduction or change of treatment. Biopsies of the upper, middle and lower thirds of the esophagus will be taken and analyzed for pathology.

05

What researchers measure

Primary outcomes

  1. Determine the rate of complete remission

    Complete remission will be defined according to the following criteria: 1. Abolition of clinical symptoms as assessed by the Pediatric Eosinophilic Esophagitis Symptom Score 2. Endoscopic score: EoE Endoscopic Reference Score (EREFS) ≤ 2 in the lower, middle and upper thirds of the esophagus. 3. Eosinophilic infiltrate \< 5/HPF in standard HES (Haemato-Eosin-Safran) stain on biopsies from lower, middle and upper thirds of esophagus 4. No therapeutic change at follow-up visit to assess remission

    Time frame: at 3 months, 6 months, 12 months, 18 months and 24 months from treatment initiation.

Secondary outcomes

  1. Description at inclusion of a cohort of pediatric patients with OE

    The description of the population will be carried out at baseline and during a 24 months follow-up at each consultation (M3, M6, M12, M18 and M24) by the patient's referring physician, listing : * demographic (age, gender, lifestyle) and medical (history, allergies, etc.) data at baseline only * Clinical data (types of symptoms, possible complications, etc.) * Paraclinical data (endoscopic and anapathic scores at diagnosis)

    Time frame: throught a 24 months follow-up

  2. evolution of quality of life

    Quality of life will be measured using the Pediatric Quality of Life Questionnaire (PedsQL Eosinophilic Esophagitis part ) currently being validated in French by our team. The PedsQL eosinophilic eosophagitis module is divided into several forms, each corresponding to different age groups with questions adapted according to age. (2-4 years, 5-7 years, 8-12 years and 13-18 years). This questionnaire is intended for children and their parents. The total score is the sum of the 35 items for 8-17 year olds, 22 for 2-4 year olds, 27 for 5-7 year olds. The maximum score is 175 for 8-17 year olds, 110 for 2-4 year olds, 135 for 5-7 year olds. The higher the score, the greater the impact of eosinophilic esophagitis on the patient's life. Nevertheless, we will also use a more general quality-of-life questionnaire, the PedsQL 4.0 Generic Core Scales in its French version.

    Time frame: at diagnosis, 3 months, 6 months, 12 months, 18 months and 24 months of treatment

06

Study locations

1 site
07

Registry details

Key details

Study ID
NCT06190080
Lead sponsor
Fondation Lenval
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Mar 2024 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jan 16, 2024

Study contacts

Mathilde Butori Pepino, MD
Contact
mathilde.butori@hpu.lenval.com
04.92.03.10.12
Marion Mouchet
Contact
marion6.mouchet@orange.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion